Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitiv...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Sehouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote, Nicole Concin
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2019-09-01
Serie:	Frontiers in Oncology
Soggetti:	recurrent ovarian carcinoma p53 mutation Hsp90 inhibitors ganetespib platinum-resistance
Accesso online:	https://www.frontiersin.org/article/10.3389/fonc.2019.00832/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!